Aurobindo Pharma Ltd

Aurobindo Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Aurobindo Pharma Ltd

₹ 1,429 -0.31%
02 Jun - close price
aurobindo.com BSE: 524804 NSE: AUROPHARMA
About

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)

Key Points

Leading Pharmaceutical Company
The company is India’s 2nd-largest listed pharma company based on revenue & the largest generics company in the US. It is ranked among the top 10 generic companies in 8 European countries. [1]

Website BSE NSE
  • Market Cap ₹ 83,008 Cr.
  • Current Price ₹ 1,429
  • High / Low ₹ 1,550 / 1,016
  • Stock P/E 23.4
  • Book Value ₹ 652
  • Dividend Yield 0.28 %
  • ROCE 12.8 %
  • ROE 10.1 %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • The company has delivered a poor sales growth of 6.32% over past five years.
  • Company has a low return on equity of 10.8% over last 3 years.
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE 200 BSE Dollex 200 Nifty 500

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
6,473 6,851 7,219 7,352 7,580 7,567 7,796 7,979 8,382 7,868 8,286 8,646 8,853
5,477 5,702 5,846 5,753 5,920 5,949 6,230 6,401 6,622 6,265 6,608 6,873 7,103
Operating Profit 996 1,149 1,373 1,599 1,660 1,618 1,566 1,578 1,760 1,603 1,678 1,773 1,750
OPM % 15% 17% 19% 22% 22% 21% 20% 20% 21% 20% 20% 21% 20%
135 47 188 163 14 221 136 159 135 107 122 123 117
Interest 56 57 68 76 89 111 113 118 115 98 95 93 98
Depreciation 346 327 418 423 354 404 382 419 444 406 429 465 479
Profit before tax 730 812 1,076 1,262 1,230 1,324 1,207 1,200 1,335 1,207 1,276 1,339 1,291
Tax % 31% 30% 30% 26% 26% 31% 32% 30% 32% 32% 34% 32% 29%
506 570 752 940 907 918 817 846 903 824 848 910 921
EPS in Rs 8.64 9.74 12.92 15.98 15.51 15.69 14.07 14.56 15.56 14.20 14.61 15.67 15.86
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
12,103 13,772 14,910 16,463 19,564 23,099 24,775 23,455 24,855 29,002 31,724 33,653
9,524 10,579 11,469 12,691 15,612 18,249 19,497 19,060 21,148 23,176 25,173 26,807
Operating Profit 2,579 3,193 3,441 3,772 3,952 4,849 5,278 4,396 3,707 5,826 6,551 6,846
OPM % 21% 23% 23% 23% 20% 21% 21% 19% 15% 20% 21% 20%
81 200 115 105 70 166 3,195 152 291 366 622 428
Interest 160 257 67 78 263 305 74 49 140 290 457 384
Depreciation 333 392 428 558 668 967 1,055 1,127 1,245 1,522 1,649 1,778
Profit before tax 2,168 2,744 3,061 3,241 3,091 3,743 7,344 3,373 2,612 4,380 5,066 5,112
Tax % 28% 26% 25% 25% 24% 24% 27% 22% 26% 28% 31% 31%
1,571 2,024 2,301 2,423 2,364 2,844 5,334 2,647 1,928 3,169 3,484 3,503
EPS in Rs 26.98 34.61 39.29 41.36 40.36 48.56 91.05 45.20 32.90 54.15 60.02 60.34
Dividend Payout % 8% 7% 6% 6% 6% 6% 4% 20% 23% 8% 0% 0%
Compounded Sales Growth
10 Years: 9%
5 Years: 6%
3 Years: 11%
TTM: 6%
Compounded Profit Growth
10 Years: 6%
5 Years: 1%
3 Years: 23%
TTM: 2%
Stock Price CAGR
10 Years: 6%
5 Years: 8%
3 Years: 29%
1 Year: 25%
Return on Equity
10 Years: 14%
5 Years: 10%
3 Years: 11%
Last Year: 10%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 29 59 59 59 59 59 59 59 59 59 58 58
Reserves 5,127 7,229 9,313 11,622 13,832 16,766 21,871 24,517 26,781 29,784 32,595 37,833
4,451 5,041 3,364 4,770 6,967 5,826 5,339 2,851 5,286 6,648 8,263 8,073
3,303 3,568 3,464 4,492 5,414 6,113 6,147 6,211 7,379 8,227 8,566 12,538
Total Liabilities 12,910 15,896 16,200 20,942 26,271 28,765 33,416 33,638 39,505 44,717 49,482 58,502
3,706 4,180 4,834 6,521 8,475 9,396 9,374 10,532 11,024 14,493 14,794 19,611
CWIP 420 848 1,458 1,583 1,668 1,986 3,062 3,747 5,390 3,869 4,900 3,009
Investments 20 123 246 312 360 555 591 997 543 372 252 1,051
8,765 10,745 9,662 12,527 15,768 16,827 20,390 18,362 22,549 25,983 29,536 34,831
Total Assets 12,910 15,896 16,200 20,942 26,271 28,765 33,416 33,638 39,505 44,717 49,482 58,502

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1,237 1,420 3,279 1,955 1,651 4,381 3,329 5,016 2,387 2,435 3,925 5,526
-1,017 -1,446 -1,787 -1,927 -2,904 -1,563 597 -3,211 -3,971 -4,242 -1,866 -3,459
93 365 -1,915 864 1,919 -1,947 -1,365 -2,969 1,814 800 120 -1,269
Net Cash Flow 313 340 -424 892 666 871 2,561 -1,164 230 -1,007 2,178 799
Free Cash Flow 491 -146 1,594 714 114 2,969 1,503 2,693 -323 -1,067 1,408 2,468
CFO/OP 67% 67% 118% 70% 61% 106% 87% 143% 84% 72% 86% 107%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 107 122 68 68 64 68 52 62 66 61 66 77
Inventory Days 239 240 246 317 304 289 333 272 275 284 295 326
Days Payable 136 146 122 128 107 97 103 97 125 129 117 151
Cash Conversion Cycle 210 217 191 257 260 260 282 237 216 216 244 252
Working Capital Days 50 44 51 50 25 35 52 84 55 66 49 52
ROCE % 27% 27% 25% 23% 18% 19% 18% 13% 9% 14% 14% 13%

Insights

In beta
Mar 2015 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Cumulative US ANDA Filings
Number

Log in to view insights

Please log in to see hidden values.

Login
Cumulative US DMF Filings
Number
Cumulative Europe Formulations Filings
Number
Number of Manufacturing Facilities
Number
Formulation Manufacturing Capacity
Billion Units
R&D Spend as % of Sales
%
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
51.84% 51.84% 51.84% 51.84% 51.80% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82%
24.12% 22.45% 20.72% 18.01% 16.73% 16.59% 16.29% 15.33% 14.38% 14.21% 13.95% 15.24%
15.73% 18.29% 20.60% 23.28% 24.77% 25.14% 25.21% 26.23% 26.93% 27.60% 27.66% 25.82%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.03% 0.05%
8.31% 7.43% 6.85% 6.87% 6.69% 6.45% 6.67% 6.61% 6.88% 6.37% 6.55% 7.08%
No. of Shareholders 2,93,2142,59,6382,41,9442,44,5752,38,6222,48,4882,57,9622,69,3232,72,2082,47,6622,36,8592,41,298

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls